Search Results for "Ventricular Fibrillation And Fat Embolism"
Original Source: PEITHO Pulmonary Embolism Thrombolysis Study
Heparin is the reference therapy for most patients with pulmonary embolism. Some patients with sub-massive pulmonary embolism defined by normal blood pressure and dysfunction of the right ventricle have a higher mortality risk. It has been suggested that thrombolytic treatment, a drug that dissolves blood clots more rapidly, may reduce the mortality in those patients. The studies reported to date were unable to confirm or refute this hypothesis because the number of patients in...
Matching Channels
Arrhythmias are abnormal rhythms of the heart and cause the heart to pump blood less effectively. Most cardiac arrhythmias are temporary and benign, often caused by strong emotions or exercise. None...
Ventricular fibrillation produces uncoordinated quivering of the ventricle with no useful contractions. It causes immediate syncope and death within minutes. Treatment is with cardiopulmonary resusc...
Matching News
New Chip Detects Intracardiac Ventricular Fibrillation
A new low-power intracardiac signal-processing chip for cardiac resynchronization therapy helps detect ventricular fibrillation.
Will Apixaban Change Practice in Atrial Fibrillation?
The oral anticoagulant apixaban was recently approved in Europe for the prevention of stroke and systemic embolism in adults with nonvalvular atrial fibrillation. What role will this agent play? Med...
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS® (apixaban) to reduce the risk of stroke and systemic...
Non-Valvular Artial Fibrillation Drug Xarelto® (Rivaroxaban), Studies Investigate Benefits
Patients with Atrial Fibrillation (AF) who undergo cardioversion or catheter ablation therapy are at particular risk of stroke and require effective anticoagulation before and after these procedures....
U.S. FDA Approves ELIQUIS (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in ...
ELIQUIS Demonstrated Superior Risk Reductions Versus Warfarin in Three Key Outcomes—Stroke and Systemic Embolism, Major Bleeding and All-Cause Mortality—for Patients with Nonvalvular Atria...
Electrical Storm, An Arrhythmic Complication, Is A Potent Risk Factor For Mortality And Morbidity
Electrical storm (ES) is a potent risk factor for mortality and morbidity, according to research presented at the ESC Congress 2012 by Dr Federico Guerra from Italy. Data was also presented on which p...
ELIQUIS(apixaban) Approved in Europe for Prevention of Stroke and Systemic Embolism in Patients ...
Only anticoagulant proven to show superior risk reductions versus warfarin in three important outcomes: stroke, major bleeding and all-cause death First approval in any market worldwide of EL...
BMS-Pfizer stroke and systemic embolism treatment approved by European Commission
Bristol-Myers Squibb and Pfizer have announced that the European Commission has approved ELIQUIS® (apixaban) for prevention of stroke and systemic embolism in adult patients with nonvalvular atrial f...
Matching PubMed Articles
Idiopathic Ventricular Fibrillation Controlled Successfully With Phenytoin.
Idiopathic Ventricular Fibrillation. We describe a case of an individual with idiopathic ventricular fibrillation whose arrhythmias were successfully controlled with phenytoin therapy. (J Cardiovasc E...
Overlooked Wolff-Parkinson-White syndrome.
An autopsy in a 28-year-old man did not explain the cause of sudden unexpected death. However, a history of episodes with tachycardia and dizziness and a reassessed previous electrocardiogram exhibiti...
Stroke severity in concomitant cardiac sources of embolism in patients with atrial fibrillation.
BACKGROUND: Atrial fibrillation (AF), which is the most common etiology of cardioembolic stroke, may be accompanied by other cardiac sources of embolism. The heterogeneity and multiplicity of the card...
More light at the end of the tunnel - apixaban in atrial fibrillation.
Introduction: Subjects with atrial fibrillation are at risk of thromboembolic events. The vitamin K antagonists (e.g., warfarin) are useful at preventing coagulation in atrial fibrillation, but are di...
Cranial and non-cranial embolism: incidence in hospitalised patients in Germany.
Using the information of the federal statistics, a detailed description of the hospitalisation rate for cranial and non-cranial embolic events in Germany is given for the years 2005-2010. Detailed lis...
